SCHEDULE 13D/A: EcoR1 Capital Boosts Zymeworks Stake to 24.2%, Secures Board Representation

Investment firm EcoR1 Capital, along with its affiliates, has increased its beneficial ownership in Zymeworks Inc. to 24.2% and secured two board seats, signaling an active investment approach.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. collectively beneficially own 16,858,418 shares of Zymeworks Inc. Common Stock, representing 24.2% of the outstanding shares.
• This percentage is calculated based on 69,576,883 shares outstanding as of March 3, 2025, as reported in Zymeworks' Form 10-K for the fiscal year ended December 31, 2024.
• The reporting persons acquired the shares for investment purposes, believing Zymeworks' Common Stock was undervalued and represented an attractive investment opportunity.
• Oleg Nodelman, manager of EcoR1 Capital, was appointed to Zymeworks' board of directors on February 17, 2025, and another EcoR1 employee, Scott Platshon, is also on the board.
• The Funds used their working capital to purchase Common Stock and Pre-Funded Warrants, with total investments of $143,465,648.26 in Common Stock and $50,999,992.79 in Pre-Funded Warrants.
• Recent purchases between March 11 and March 17, 2025, involved 1,138,257 shares at dollar-weighted average prices ranging from $11.4935 to $12.4846 per share.
• The reporting persons hold 5,086,521 Pre-Funded Warrants, which are currently not exercisable if, after exercise, beneficial ownership would exceed 19.99% of the total outstanding Common Stock.
• A Registration Rights Agreement requires Zymeworks to register the resale of Warrant Shares, with potential liquidated damages of 1% of the aggregate purchase price for shares held (not unissued warrants) for each 30-day period of delay, capped at 6% in aggregate.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A significant increase in ownership by a specialized investment firm, coupled with board representation, suggests strong investor confidence and potential for strategic improvements. However, the document is a disclosure of ownership and intent, not a performance report, so it doesn't reflect immediate operational success or provide new financial results.

Positives

• Significant investment by EcoR1 Capital, a specialized life sciences investment firm, indicating strong conviction in Zymeworks' undervaluation and future prospects.
• EcoR1 Capital has secured two board seats, including for its manager Oleg Nodelman, which could bring valuable strategic oversight and enhance shareholder alignment.
• The acquisition of Pre-Funded Warrants provides additional potential upside for EcoR1 Capital without immediate dilution impact, demonstrating a long-term investment horizon.
• The reporting persons' stated intention to actively monitor the Issuer's operations, assets, and strategic matters suggests a commitment to enhancing shareholder value.

Negatives

• The 19.99% beneficial ownership limitation on Pre-Funded Warrants restricts EcoR1's immediate ability to fully exercise these warrants and increase their direct shareholding beyond the current threshold.
• Zymeworks faces potential liquidated damages of 1% of the aggregate purchase price for shares held (not unissued warrants) for each 30-day period if it fails to meet registration deadlines for the Warrant Shares, capped at 6% in aggregate.
• The document does not provide specific financial performance metrics for Zymeworks, making it difficult to assess the company's current operational health from this filing alone.

Risks

• Beneficial Ownership Limitation: The 19.99% beneficial ownership limitation on Pre-Funded Warrants restricts the reporting persons' ability to fully convert their warrants into common stock, potentially limiting their direct influence or liquidity.
• Registration Delays: If Zymeworks fails to meet the filing or effectiveness deadlines for the registration statement covering the Warrant Shares, it will be subject to liquidated damages of 1% of the aggregate purchase price for shares held (not unissued warrants) for each 30-day period of delay, up to a maximum of 6%.
• Investment Risk: The reporting persons acquired the stock based on their belief that it was undervalued, which is an investment opinion and subject to market fluctuations and company performance.
• Activist Investor Influence: While board representation can be positive, an activist investor's recommendations could lead to strategic shifts that may or may not align with all shareholder interests or prove successful.

Future Outlook

The reporting persons intend to routinely monitor Zymeworks regarding various factors including current and anticipated future trading prices, operations, assets, prospects, financial position, business development, management, competitive and strategic matters, and general economic conditions. They may purchase or sell additional shares, enter into hedging or other derivative transactions, or pledge their interests. While they have no present plan for specific corporate actions such as mergers or changes in control, they may recommend actions to Zymeworks' management, board, and stockholders, which could potentially involve such significant corporate events.

Management Comments

• "The reporting persons acquired the Stock for investment purposes based on their belief that the Issuer's Common Stock, when purchased, was undervalued and represented an attractive investment opportunity."
• "The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations, including, current and anticipated future trading prices of the Common Stock and other securities, the Issuer's operations, assets, prospects, financial position, and business development, Issuer's management, Issuer-related competitive and strategic matters, general economic, financial market and industry conditions, and other investment considerations."
• "The reporting persons have no present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. However, the reporting persons may recommend action to the Issuer's management, board of directors and stockholders."

Industry Context

This filing indicates a significant activist investment in the biotechnology sector. EcoR1 Capital specializes in life sciences, suggesting a strategic interest in Zymeworks' pipeline or technology. Such large stakes and board representation by specialized investors often precede strategic shifts, increased focus on R&D efficiency, or potential M&A activities within the competitive biotech landscape, aiming to unlock perceived undervaluation.

Management Changes

Corporate Governance

Related Party Transactions

• Securities Purchase Agreement dated December 23, 2023, between Zymeworks Inc. and the reporting persons (EcoR1 Capital, LLC, Oleg Nodelman, EcoR1 Capital Fund Qualified, L.P.) for the purchase of 5,086,521 pre-funded warrants and the right for EcoR1 to nominate a director.
• Registration Rights Agreement dated December 23, 2023, between Zymeworks Inc. and the reporting persons, requiring Zymeworks to register the resale of the warrant shares.
• The appointment of Oleg Nodelman and Scott Platshon (employees of EcoR1 Capital) to Zymeworks' board of directors, stemming from the Securities Purchase Agreement.

Stakeholder Impact

• Shareholders: Increased institutional ownership by an activist investor could lead to enhanced focus on shareholder value, potential strategic changes, and improved corporate governance. However, it also introduces the possibility of activist-driven initiatives that may not align with all shareholder preferences.
• Management/Employees: The presence of EcoR1 representatives on the board could lead to increased scrutiny of operational efficiency, strategic direction, and potentially changes in management or business focus.
• Creditors: No direct impact mentioned, but any strategic shifts or capital allocation decisions influenced by the new board members could indirectly affect the company's financial health and credit profile.

Next Steps

• Reporting persons will routinely monitor Zymeworks' operations, assets, prospects, financial position, and business development.
• Reporting persons may purchase additional Common Stock or sell existing holdings in the open market or privately negotiated transactions.
• Reporting persons may enter into or unwind hedging or other derivative transactions with respect to the Common Stock.
• Reporting persons and their representatives may communicate with other stockholders, industry participants, and interested parties about Zymeworks.
• Reporting persons may recommend actions to Zymeworks' management, board of directors, and stockholders, potentially involving significant corporate events such as mergers or changes in capitalization.
• Zymeworks is obligated to file a registration statement for the resale of Warrant Shares by the earlier of March 15, 2024, or the first business day after its 2023 Form 10-K filing.
• Zymeworks is obligated to cause the registration statement to be declared effective by the later of April 29, 2024, or the 123rd calendar day following the closing date of the Securities Purchase Agreement.

Key Dates

Keywords

Zymeworks Inc., EcoR1 Capital, Schedule 13D, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Biotechnology, Investment Firm, Board of Directors, Shareholder Activism, SEC Filing, Corporate Governance, Investment Strategy